ARTICLE SUMMARY:
Cognito’s noninvasive investigational device therapy for Alzheimer’s disease appears to be safe and has demonstrated promising effectiveness at slowing the rate of cognitive decline.
Cognito Therapeutics, which is developing a first-in-class investigational device therapy for Alzheimer’s Disease (AD), is in its last mile to the finish. Enrollment is nearly complete for the company’s 670-participant pivotal trial HOPE, which is studying the efficacy of Spectris, a noninvasive disease-modifying device therapy. CEO Christian Howell expects the randomized, sham-controlled 12-month study to read out in the first half of 2026. The company, which has raised about $128 million to date, is now raising a Series C round to get it through that last mile.
Founded in 2016, Cognito’s platform rests on decades of research on the role of gamma waves in brain health, specifically by the team at MIT who founded the company. Rather than targeting, as some monoclonal antibody-based therapies do, the protein pathology of AD, that is, the over-abundance of amyloid-ß or tau proteins in the diseased brain, Cognito’s scientific founders Ed Boyden, PhD, and Li-Huei Tsai, PhD, set out to essentially reverse engineer what happens in a healthy brain.
